Clinical trials in Oldenburg In Holstein – page 29

840 clinical trials in Oldenburg In Holstein, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Oldenburg In Holstein at a glance

840

clinical trials

Research sites1

Quick filters

840 trials in Oldenburg In Holstein

Open in trial search

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Amlitelimab
Sponsor:Scleroderma Research Foundation

Contact Research Centre

Psoriasis

Not yet recruiting

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Janssen Cilag International

Contact Research Centre

Psoriasis

Not yet recruiting

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Janssen Cilag International

Contact Research Centre

Obesity+2

Not yet recruiting

Phase 3 Randomized Trial of Once‑Monthly PF‑08653944 to Reduce Breathing Events in Adults with Obstructive Sleep Apnea and Overweight/Obesity Using a PAP Machine

Investigational

Phase 3 Randomized Trial of Once‑Monthly PF‑08653944 to Reduce Breathing Events in Adults with Obstructive Sleep Apnea and Overweight/Obesity Using a PAP Machine

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Berobenatide
Sponsor:Pfizer Inc.

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Phase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer

Registered drugNo placebo

Phase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Lichen planopilaris

Not yet recruiting

Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2/3 Study

Investigational

Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2/3 Study

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Priovant Therapeutics Inc.

Contact Research Centre

Cutaneous sarcoidosis

Not yet recruiting

A Phase 2/3 Study of the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

Investigational

A Phase 2/3 Study of the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Priovant Therapeutics Inc.

Contact Research Centre

Lichen planus

Not yet recruiting

Efficacy and safety of GIA632 versus placebo in adults with moderate to severe cutaneous lichen planus

Registered drug

Efficacy and safety of GIA632 versus placebo in adults with moderate to severe cutaneous lichen planus

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:GIA632
Sponsor:Novartis Pharma AG

Contact Research Centre

Squamous cell carcinoma of head and neck

Not yet recruiting

Phase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Phase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ficerafusp alfa
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Vividion Therapeutics Inc.

Contact Research Centre

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Oldenburg In Holstein

What the registry says about research in the country

01 Metabolic Disorders

Innovative clinical trials focusing on Type 2 Diabetes management and treatments, including studies of novel weekly insulin alternatives and oral medications for glycemic control.

Glycemic Control Studies
Insulin Alternatives Research
Cardiovascular Outcomes

Multiple studies evaluating new therapeutic approaches for better diabetes management and reducing cardiovascular risks.

02 Weight Management

Comprehensive research into obesity treatment and weight-related conditions, examining new therapeutic combinations and their effects on weight loss and associated health conditions.

Weight Loss Interventions
Obesity Medications
Comorbidity Management

Studies focusing on innovative approaches to weight management and treating obesity-related health complications.

03 Cardiovascular Health

Research examining treatments for atherosclerotic cardiovascular disease and related conditions, with emphasis on preventing major adverse cardiovascular events.

Cardiovascular Risk Reduction
Lipid Management
Preventive Therapies

Trials evaluating new medications for improving cardiovascular outcomes in high-risk patients.

04 Gastrointestinal Studies

Clinical investigations of treatments for Crohn's Disease and other digestive conditions, focusing on long-term efficacy and safety of new therapeutic approaches.

Inflammatory Bowel Disease
Long-term Treatment Outcomes
Disease Management

Studies aimed at improving quality of life for patients with chronic gastrointestinal conditions.

05 Oncology Research

Advanced studies in colorectal cancer treatment and management, including innovative approaches to Stage II and III cancer therapy.

Cancer Treatment Protocols
Disease-Free Survival
Adjuvant Therapy

Trials evaluating new treatment strategies for improving outcomes in cancer patients.

Back to Germany All countries